HANSA BIOPHARMA

Søren Tulstrup, President & CEO

14 May 2024



Hansa Biopharma – a biotech to believe in

Commercial stage, science driven biotechnology company in Sweden with financing through 2026

At a Glance

- **2007** founded in Lund
- **160** employees globally
- **$170M** market cap
- **$34.6M** recent financing round

Purpose driven Culture

- **33** different nationalities
- **4th year** Great Place to Work® certified
- **18%** reduction in energy consumption*

Proprietary technology platform

- **Autoimmune**
- **Gene Therapy**
- **Transplantation**

PORTFOLIO

IMLIFIDASE
1st in class IgG cleaving molecule

HNSA-5487
Next-gen IgG cleaving molecule

PIPELINE

Two Phase 1
✓ 5487 FIH, DMD gene therapy

Three Phase 2
✓ AMR, GBS, ANCA (IIT)

Three Phase 3
✓ US kidney, EU post approval, anti-GBM

*according to 2023 Sustainability Report

Broad clinical pipeline in transplantation, autoimmune diseases, and gene therapy

Project	Indication	Research/ Preclinical	Phase 1	Phase 2	Phase 3	Marketing Authorization	Marketed	Partner	Next Anticipated Milestone
Imlifidase	EU: Kidney transplantation in highly sensitized patients[1,2]								EU: Additional agreements around reimbursement / Post approval study to be completed by 2025
	U.S. "ConfIdeS": Kidney transplantation in highly sensitized patients[1,2]								Completion of randomization (64 patients) mid 2024
	GOOD-IDES-02: Anti-GBM antibody disease								Complete enrollment (50 patients)
	16-HMedIdes-12: Active Antibody Mediated Rejection (AMR)								Publication in peer-reviewed journal
	15-HMedIdeS-09: Guillain-Barré Syndrome (GBS)								Comparative efficacy analysis 2024
	Investigator-initiated trial in ANCA-associated vasculitis[3]								Complete enrollment (10 patients)
	SRP-9001-104: Pre-treatment ahead of gene therapy in Duchenne Muscular Dystrophy (DMD)		Phase 1b					**Sarepta Therapeutics**	Completion of enrollment
	Pre-treatment ahead of gene therapy in Limb-Girdle Muscular Dystrophy (LGMD)							**Sarepta Therapeutics**	Preclinical research
	Pre-treatment ahead of gene therapy in Pompe disease							**AskBio**	Preclinical research
	Pre-treatment ahead of gene therapy in Crigler-Najjar syndrome							**Genethon**	Commence clinical study
HNSA-5487	NICE-01 phase 1: HNSA-5487 – Lead candidate from the NiceR program								Further analysis around endpoints from Phase 1 to be completed in 2024 incl. selection of lead indication

Completed | Ongoing | Planned | Post approval study running in parallel with commercial launch

[1] Results from the Phase 1 study have been published, Winstedt et al. (2015) PLOS ONE 10(7)
[2] Lorant et al., American Journal of Transplantation and 03+04 studies (Jordan et al., New England Journal of Medicine)
[3] Investigator-initiated study by Dr. Adrian Schreiber and Dr. Philipp Enghard, at Charité Universitätsmedizin, Berlin, Germany

Imlifidase is an innovative, first in class molecule with a novel approach to eliminate pathogenic IgG

Originates from a bacteria
Streptococcus pyogenes known from causing a strep throat infection

IgG antibody-cleaving enzyme
Interacts with Fc-part of IgG with extremely high specificity

Inactivates IgG in 2-6 hours
Rapid onset of action that inactivates IgG below detectable level in 2-6 hours

Unique MOA cleaves IgG creating an IgG free window for approximately one week



*The 5-year data is a continuation of the analysis at 3-years of crossmatch positive patients published in the *American Journal of Transplantation*

7 clinical trials in key disease areas

- **Autoimmune**
- **Gene Therapy**
- **Transplantation**

First & only treatment approved for desensitization

EU Approval**
in kidney TX as IDEFIRIX®

75%
access in the EU transplant market

2025
planned US BLA filing; US trial ongoing

*IDEFIRIX approved in EEA under conditional approval for kidney transplantation

AUTOIMMUNE



Imlifidase may have relevance in several autoimmune diseases where IgG plays an important role in the pathogenesis

+100 autoimmune diseases

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin disorders
- Blood disorders

Pivotal phase 3 trial in anti-GBM to evaluate kidney function after 6 months



- 1,200 people affected in US and EU annually
- Standard of care deemed insufficient
- Ph 3 trial 50% enrolled

Catalyst to more IgG mediated conditions



Combination and stand-alone

☐ Potential autoimmune indications (currently not pursued)
■ Clinical programs

*Total disease populations in EU & US, based on prevalence and population data

GENE THERAPY



Imlifdase may enable gene therapy treatment in rare disease patients with pre-existing antibodies

AAVs
the delivery system of gene therapy

5-70%
patients considered for gene therapy have anti-AAV antibodies

Pre-existing antibodies
excludes patients from trials & treatment

Eliminate antibodies as a pre-treatment to enable gene therapy



- **Significant unmet need**
- **Encouraging pre-clinical data**
- **Partnership strategy**

Global partnerships with gene therapy companies

SAREPTA THERAPEUTICS

- World leader within gene therapy targeted at muscular dystrophies
- High level read out in DMD expected 2024

AskBio

- Early innovator in gene therapy
- Encouraging Ph 1 data presented at ASGCT 2024

GENETHON
CURE THROUGH INNOVATION

- A not-for-profit pioneer in gene therapies
- Preclinical work underway in Crigler Najjar syndrome

TRANSPLANTATION



Imlifidase may enable incompatible kidney Tx in highly sensitized patients

100k*	**DSAs**	**SOC**	**10-15%**
patients waiting for a kidney transplant	Donor specific antibodies that reject organ transplantation	based on organ compatibility	patients with DSAs – or highly sensitized - unlikely to be transplanted due to incompatibility

**In the US

Long term data in kidney transplantation confirms sustained benefit of imlifidase



- 82% five-year graft survival
- 90% patient survival rate
- 50 ml/min/m2 eGFR

EU Approval** as desensitization treatment as IDEFIRIX®

Addresses the limitations of other modalities

The **first and only** approved drug to enable incompatible kidney transplants

Market access in 75% of the EU transplant market

**IDEFIRIX approved in EEA under conditional approval for kidney transplantation

HNSA-5487 is a next gen enzyme with long and short interval redosing potential

Lower immunogenicity
could apply to diseases where prolonged or intermittent IgG free window is needed

Short interval redosing
create a longer IgG-low period

Long interval redosing
keeps IgG at a low level, potentially leading to greater efficacy vs monotherapy

Encouraging high level Ph 1 study results

single ascending dose in 36 healthy volunteers

- Administration was safe and well tolerated
- Fast and complete cleavage of IgG; PK in line with expectations
- Further analysis and lead indication selection completed in 2024

Potential indication landscape

through two different redosing regimens


HANSA
BIOPHARMA